Detalles de la búsqueda
1.
Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions.
CA Cancer J Clin
; 73(6): 620-652, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37329269
2.
An IL-4 signalling axis in bone marrow drives pro-tumorigenic myelopoiesis.
Nature
; 625(7993): 166-174, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-38057662
3.
RANK rewires energy homeostasis in lung cancer cells and drives primary lung cancer.
Genes Dev
; 31(20): 2099-2112, 2017 10 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-29118048
4.
Small cells - big issues: biological implications and preclinical advancements in small cell lung cancer.
Mol Cancer
; 23(1): 41, 2024 02 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-38395864
5.
Baseline extracellular vesicle TGF-ß is a predictive biomarker for response to immune checkpoint inhibitors and survival in non-small cell lung cancer.
Cancer
; 129(4): 521-530, 2023 02 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-36484171
6.
Protein Expression of immune checkpoints STING and MHCII in small cell lung cancer.
Cancer Immunol Immunother
; 72(3): 561-578, 2023 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-35978199
7.
Expression patterns and prognostic relevance of subtype-specific transcription factors in surgically resected small-cell lung cancer: an international multicenter study.
J Pathol
; 257(5): 674-686, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35489038
8.
The presence of circulating genetically abnormal cells in blood predicts risk of lung cancer in individuals with indeterminate pulmonary nodules.
BMC Pulm Med
; 23(1): 193, 2023 Jun 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-37277788
9.
Targeted Next-Generation Sequencing Reveals Exceptionally High Rates of Molecular Driver Mutations in Never-Smokers With Lung Adenocarcinoma.
Oncologist
; 27(6): 476-486, 2022 06 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35298662
10.
Loss of STING expression is prognostic in non-small cell lung cancer.
J Surg Oncol
; 125(6): 1042-1052, 2022 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-35099823
11.
Analysis of Real-World Data to Investigate the Impact of Race and Ethnicity on Response to Programmed Cell Death-1 and Programmed Cell Death-Ligand 1 Inhibitors in Advanced Non-Small Cell Lung Cancers.
Oncologist
; 26(7): e1226-e1239, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-33829580
12.
A composite biomarker of neutrophil-lymphocyte ratio and hemoglobin level correlates with clinical response to PD-1 and PD-L1 inhibitors in advanced non-small cell lung cancers.
BMC Cancer
; 21(1): 441, 2021 Apr 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-33882890
13.
Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1).
Proc Natl Acad Sci U S A
; 115(43): E10119-E10126, 2018 10 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-30297397
14.
Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol.
Lancet Oncol
; 21(12): 1589-1601, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-33125909
15.
"Interchangeability" of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy.
Mod Pathol
; 33(1): 4-17, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31383961
16.
Reanalysis of the NCCN PD-L1 companion diagnostic assay study for lung cancer in the context of PD-L1 expression findings in triple-negative breast cancer.
Breast Cancer Res
; 21(1): 72, 2019 06 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-31196152
17.
EGFR-TKIs plus local therapy demonstrated survival benefit than EGFR-TKIs alone in EGFR-mutant NSCLC patients with oligometastatic or oligoprogressive liver metastases.
Int J Cancer
; 144(10): 2605-2612, 2019 05 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-30387880
18.
Prognostic impact of tumor mutation burden and the mutation in KIAA1211 in small cell lung cancer.
Respir Res
; 20(1): 248, 2019 Nov 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-31699089
19.
Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study.
Lancet Oncol
; 19(1): 101-114, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29169877
20.
Long-term safety and survival with gefitinib in select patients with advanced non-small cell lung cancer: Results from the US IRESSA Clinical Access Program (ICAP).
Cancer
; 124(11): 2407-2414, 2018 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29579334